Will Altria Buy Out Cronos (TSX:CRON) Stock?

Cronos Group Inc (TSX:CRON)(NASDAQ:CRON) stock is suffering during the coronavirus bear market. Could Altria Group (NYSE:MO) buy the company?

| More on:
Dice engraved with the words buy and sell

Image source: Getty Images.

Altria Group (NYSE:MO) is a giant company. Now valued at $70 billion, the tobacco behemoth has advantages that smaller competitors simply don’t possess. In today’s environment, Altria’s access to capital is most prized of all.

There’s a chance the company could use its power to completely acquire its cannabis partner, Cronos Group Inc (TSX:CRON)(NASDAQ:CRON).

In December of 2018, Altria and Cronos agreed to a landmark deal. Altria purchased $1.8 billion in the pot company’s stock, giving it a 45% interest. Altria retained warrants that would increase its ownership to 55% at a price of $19 per share.

“The proceeds from Altria’s investment will enable us to more quickly expand our global infrastructure and distribution footprint, while also increasing investments in R&D and brands that resonate with our consumer,” Cronos CEO Mike Gorenstein said.

“We are very excited about the future prospects of the cannabis industry and the opportunity for Cronos to position itself for long-term leadership,” concluded Altria CFO Billy Gifford.

The partnership deal originally closed at nearly $20 per share. Today, CRON stock trades at a 70% discount. With a bargain valuation, it’s growing likely that Altria will completely acquire the cannabis producer.

Connect the dots

Altria was formerly the U.S. subsidiary of Philip Morris International Inc. It’s now an independent company focused completely on the American market. While this focus allows it to invest more strategically, it also leaves the company more vulnerable to domestic shifts.

In 1965, more than 40% of U.S. residents regularly smoked cigarettes. That figure has fallen nearly every year since. Today, smokers represent less than 15% of the adult population.

The decline in smoking has created new markets, particularly for vaping and marijuana consumption. Shifts in behaviour were the impetus behind Altria’s multi-billion dollar investments in vape manufacturer Juul and cannabis producer Cronos.

In hindsight, it’s clear that Altria overpaid for its Cronos stake. The firm has quickly lost more than half of its original investment. But the company wasn’t in it for the short term. Altria built its success last century on age-old products, but the next several decades will rely on newer offerings like vapes and cannabis. This is the definition of a long-term bet.

Time to buy Cronos stock?

At today’s prices, it’s difficult to see why Altria wouldn’t pull the trigger and acquire the remainder of Cronos stock. The company already controls more than half the board seats, and the valuation is getting ridiculous.

Last quarter, Cronos had US$1.3 billion in cash and $0 in long-term debt. Its market cap is just US$1.9 billion. Backing out the cash, Altria can acquire the company for only $600 million, plus any premium versus the trailing share price.

After paying $1.8 billion for roughly half the business, why wouldn’t Altria acquire the rest at one-third the price?

A $600 million investment would mean very little compared to Altria’s $70 billion market cap. Plus, Altria has more than US$5 billion in cash on the balance sheet.

The dots here are easy to connect. Altria can acquire the rest of Cronos while barely impacting its financial situation.

The company already showed its hand by making a $1.8 billion investment in 2018. Expect the company to take full control in the near-term.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ryan Vanzo has no position in any stocks mentioned.

More on Coronavirus

A airplane sits on a runway.
Coronavirus

3 Things to Know About Air Canada Stock Before You Buy

Air Canada stock continues to hover below $20 despite the sharp rise in travel demand seen across the industry. What's…

Read more »

tech and analysis
Stocks for Beginners

If You Invested $1,000 in WELL Health in 2019, Here is What It’s Worth Now

WELL stock (TSX:WELL) has fallen pretty dramatically from all-time highs, but what if you bought just before the rise? Should…

Read more »

Hand arranging wood block stacking as step stair with arrow up.
Coronavirus

2 Pandemic Stocks That Are Still Rising, and 1 Offering a Major Deal

There are some pandemic stocks that crashed and burned, while others have made a massive comeback. And this one stock…

Read more »

Dad and son having fun outdoor. Healthy living concept
Dividend Stocks

1 Growth Stock Down 15.8% to Buy Right Now

A growth stock is well-positioned to resume its upward momentum in 2024 following its strong financial results and business momentum.

Read more »

Double exposure of a businessman and stairs - Business Success Concept
Stocks for Beginners

3 Things About Couche-Tard Stock Every Smart Investor Knows

Couche-tard stock (TSX:ATD) may be up 30% this year, but look at the leadership and history of the stock to…

Read more »

Plane on runway, aircraft
Coronavirus

Can Air Canada Double in 5 Years? Here’s What it Would Take

Air Canada (TSX:AC) stock has gone nowhere since 2020. Can this change?

Read more »

Senior housing
Stocks for Beginners

Home Improvement Stocks Are Set to Fall (When They Do, Buy These Like Crazy!)

Home improvement stocks are due to drop further in the coming months. But with solid underpinnings for the sector, it…

Read more »

An airplane on a runway
Coronavirus

Forget Boeing: Buy This Magnificent Airline Stock Instead

Boeing (NYSE:BA) stock is looking risky right now, but Air Canada (TSX:AC) stock? Much less so.

Read more »